|
|
|
|
Document Preview Lorus Therapuetics Announces Global Expansion of the Virulizin Registration Phase III Clinical Trial |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Lorus Therapuetics Announces Global Expansion of the Virulizin Registration Phase III Clinical Trial |
|||
|
Entities: |
||||
|
Date: |
2003 |
|||
|
Size: |
Preview shows 2KB of 6KB total |
|||
|
Price: |
$39 |
|||
|
ID: |
#279473 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Hugh Mansfield Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (416) 370-5045
Email: ir@lorusthera.com Email: hugh@mcipr.com Email: jennifer@mcipr.com
{/Table}
LORUS THERAPUETICS ANNOUNCES GLOBAL EXPANSION OF THE VIRULIZIN
REGISTRATION PHASE III CLINICAL TRIAL
- Expansion of Phase III clinical trial in advanced pancreatic cancer to
Europe and South America -
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, SEPTEMBER 30, 2003 - Lorus Therapeutics Inc. ("Lorus")
announced today a major global expansion to clinical sites in Europe and South
America of its current Phase III clinical trial of Virulizin in advanced
pancreatic cancer. The clinical study is now operating at major oncology centres
in Russia, Ukraine, and Romania, with additional sites in Poland, the Czech
Republic, Hungary, Spain and Brazil in progress. The study is also ongoing at
centres in the US, Canada and Mexico. To date, over 100 clinical study sites are
involved in this international Phase III clinical trial.
The Virulizin Phase III trial in advanced pancreatic cancer is a multi-centre,
double-blind clinical study comparing Virulizin in combination with gemcitabine
to gemcitabine and placebo in the first-line treatment setting. The study also
includes a second-line treatment component involving Virulizin in combination
with 5-FU, versus 5-FU and placebo.
The primary efficacy endpoint of the study is survival. Secondary endpoints in
the study include time to treatment progression, which analyzes the effect of
Virulizin on key clinical benefit parameters such as pain, analgesic
consumption, changes in weight, and performance status.
In addition, the study will also correlate immune parameters with clinical
|
End of Preview |
Home Intelligence Services Subscriptions News About Us